US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two

The U.S. Food and Drug Administration has expanded the approval of Vertex Pharmaceuticals' gene therapy for sickle cell disease to include pediatric patients as young as two years old. This regulatory milestone broadens the reach of a treatment for a debilitating genetic blood disorder that can cause severe pain and long-term health complications. For the pharmaceutical sector, this expansion represents a significant step in the commercialization and accessibility of gene therapies for younger populations. The decision highlights the agency's willingness to authorize advanced genetic treatments for pediatric use following initial adult approvals.